Literature DB >> 23053998

Estimation of cell membrane properties and erythrocyte red-ox balance in patients with metabolic syndrome.

Edward Kowalczyk1, Jan Kowalski, Jan Błaszczyk, Łukasz Gwoździński, Julita Ciećwierz, Monika Sienkiewicz.   

Abstract

Metabolic syndrome (MS) is associated with occurrence of the many cardiovascular risk factors such as atherogenic dyslipidemia, visceral fat distribution, arterial hypertension and pro-thrombotic and pro-inflammatory status. In our study the effect of disorders that appear in MS on red-ox balance and erythrocyte cell membrane properties were estimated. The study comprised 50 patients with diagnosed MS and in 25 healthy subjects. Content of thiobarbituric acid reactive substances (TBARS) and catalase, superoxide dismutase and glutathione peroxidase activity were estimated in red blood cells. Moreover, conformation status of membrane proteins, membrane fluidity and osmotic fragility were evaluated. MS was found to manifest: (1) the increase of the concentration of TBARS in erythrocytes with no statistically significant differences in antioxidant enzymes activity, (2) disorders in the structure of erythrocyte cytoskeleton proteins, (3) the increase in membrane lipids fluidity at the depth of 5th and 12th carbon atom of fatty acid hydrocarbon chain and significantly decreased fluidity at the depth of 16th carbon atom, (4) increased erythrocyte osmotic fragility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053998      PMCID: PMC3487009          DOI: 10.1007/s11033-012-2017-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  27 in total

1.  Prognostic significance of endothelial dysfunction in hypertensive patients.

Authors:  F Perticone; R Ceravolo; A Pujia; G Ventura; S Iacopino; A Scozzafava; A Ferraro; M Chello; P Mastroroberto; P Verdecchia; G Schillaci
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

2.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

Authors:  J A Suwaidi; S Hamasaki; S T Higano; R A Nishimura; D R Holmes; A Lerman
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

3.  A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase.

Authors:  R F BEERS; I W SIZER
Journal:  J Biol Chem       Date:  1952-03       Impact factor: 5.157

Review 4.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

Review 5.  Membrane fluidity in malignancy. Adversative and recuperative.

Authors:  M Shinitzky
Journal:  Biochim Biophys Acta       Date:  1984

6.  Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients.

Authors:  S K Jain; R McVie
Journal:  Diabetes       Date:  1999-09       Impact factor: 9.461

7.  Direct measurement of erythrocyte deformability in diabetes mellitus with a transparent microchannel capillary model and high-speed video camera system.

Authors:  K Tsukada; E Sekizuka; C Oshio; H Minamitani
Journal:  Microvasc Res       Date:  2001-05       Impact factor: 3.514

8.  Properties of vitamin E-deficient erythrocytes following peroxidant injury.

Authors:  B Lubin; D Chiu
Journal:  Pediatr Res       Date:  1982-11       Impact factor: 3.756

Review 9.  The pathogenesis of atherosclerosis: a perspective for the 1990s.

Authors:  R Ross
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

10.  Influence of cholesterol content on red cell membrane viscoelasticity and fluidity.

Authors:  A Chabanel; M Flamm; K L Sung; M M Lee; D Schachter; S Chien
Journal:  Biophys J       Date:  1983-11       Impact factor: 4.033

View more
  1 in total

1.  Association of altered hemorheology with oxidative stress and inflammation in metabolic syndrome.

Authors:  Prajwal Gyawali; Ross S Richards
Journal:  Redox Rep       Date:  2014-12-12       Impact factor: 4.412

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.